Copenhagen, Denmark, May 19, 2025 - Zealand Pharma A/S has appointed Steven Johnson as Chief Development Officer. He joins the executive team alongside Chief Medical Officer David Kendall and recently appointed Chief Scientific Officer Utpal Singh. Johnson will lead regulatory and development strategies, enhancing Zealand Pharma's focus on innovation in managing obesity and related conditions. Johnson brings nearly 30 years of experience from his previous roles at UCB Biopharma, Medpace, Inc., Novo Nordisk, and the U.S. Food and Drug Administration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.